{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.7.', 'Other Assessments', '11.7.1.', 'C-reactive Protein and Collection of Information on Antineoplastic Therapy', 'C-reactive protein will be measured and information on any antineoplastic therapies planned to', 'be used or used after discontinuation of study treatment will be collected.', '11.7.2.', 'Nutritional Consultation', 'Patients must be given nutritional consultation to discuss any food recommendations and', 'strategies for managing potential nausea and appetite changes experienced with selinexor.', '11.7.3.', 'Telephone Contacts', 'A telephone call will be performed at the following time points:', 'Selinexor-containing regimens only: On C1D3, 2 days following the first dose of', 'selinexor on C1D1. The purpose of this telephone call is to evaluate supportive care', 'medications, concomitant medications, and AEs, and to adjust supportive care as', 'appropriate. The contact with the patient must take place on C1D3, 2 days following', 'the first dose of selinexor on C1D1.', 'At the Safety Follow-up. The purpose of this telephone call with the patient is to', 'assess the overall medical condition of the patient and status of their MM, follow up', 'on any AEs that were not resolved at the EoT Visit, and collect information regarding', 'any antineoplastic therapies used after discontinuation of study treatment.', '11.7.4.', 'Durability of Response and Survival Follow-up Visit(s)', 'After discontinuation of SVd, Vd, SVdX, or SdX if feasible and clinically indicated, the', 'following assessments should be performed at Durability of Response and Survival Follow-up', 'Visits for patients who have not progressed to assess durability of response: SPEP with serum', 'protein immunofixation, UPEP (24-hr) with urine protein immunofixation, quantitative Ig levels,', 'and serum FLC (and physical examinations and imaging for bone lesions and plasmacytomas', \"and bone marrow aspirate, if clinically indicated, per Investigator's discretion). If these\", 'assessments cannot be performed, at a minimum, a telephone call will be made to the patient (or', \"the patient's family) to assess the survival status, status of the patient's MM, and overall medical\", 'condition of the patient and collect information on any antineoplastic therapies used after', 'discontinuation of study treatment.', 'Confidential', 'Page 85', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '12.', 'SAFETY DEFINITIONS, RECORDING, AND REPORTING', \"Note: For urgent medical issues in which the study's Medical Monitor should be contacted,\", 'please refer to the Study Manual for complete contact information.', '12.1.', 'Adverse Events', '12.1.1.', 'Definitions', 'Adverse event (AE): Any untoward medical occurrence in a patient or clinical', 'investigation subject administered a pharmaceutical product and which does not', 'necessarily have to have a causal relationship with this treatment. An AE can', 'therefore be any unfavorable and unintended sign (including an abnormal laboratory', 'finding, for example), symptom, or disease temporally associated with the use of', 'study treatment, whether or not considered related to the study treatment.', 'Treatment-emergent adverse event (TEAE): Any event that was not present prior to', 'the initiation of study treatment or any event already present that worsens in either', 'intensity or frequency following exposure to study treatment.', 'Adverse event of special interest (AESI): Any AE (serious or nonserious) that is of', 'scientific and medical concern specific to the study treatment, for which ongoing', 'monitoring and rapid communication by the Investigator to the Sponsor is', 'appropriate.', 'Serious adverse event (SAE): Any untoward medical occurrence that, at any dose,', 'results in death; is life threatening (ie, an event in which the patient was at risk of', 'death at the time of the event; it does not refer to an event that hypothetically might', 'have caused death if it were more severe); requires inpatient hospitalization or', 'prolongation of existing hospitalization; results in persistent or significant', 'disability/incapacity; or is a congenital anomaly/birth defect. (See Section 12.2.3 for', 'additional information about SAE reporting.)', '12.1.2.', 'Recording of Adverse Events', 'All AEs that begin or worsen after the patient has provided informed consent will be recorded on', 'the Adverse Events eCRF, regardless of whether dosing with study drug has commenced. For', 'events that are considered by the Investigator to be related to the study drug, the monitoring of', 'the AE should be continued through the end of the study, for at least 30 days following the last', 'dose of study drug, or until resolution.', 'Adverse events (including laboratory abnormalities that constitute AEs) should be described', 'using a diagnosis whenever possible, rather than individual underlying signs and symptoms.', 'When a clear diagnosis cannot be identified, each sign or symptom should be recorded as a', 'separate AE.', 'The Investigator should ask the patient non-leading questions to determine if any AEs have', 'occurred during the study, since the last study visit. Adverse events may also be recorded when', 'they are volunteered by the patient, or through physical examination, laboratory tests, or other', 'clinical assessments.', 'Confidential', 'Page 86', 'Version 4.0']\n\n###\n\n", "completion": "END"}